-

While There Are Still Unknowns, Monoclonal Antibodies Can Help in the Fight Against COVID-19

Antibodies have the Potential to Effectively Target Several Stages of the Disease with Evident Benefits at a Patient Level and a Systemic Level, According to a New White Paper by Trinity Life Sciences

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest white paper entitled “Beyond Vaccines – How Monoclonal Antibodies Can Help in the Fight Against the COVID-19 Pandemic.” The paper finds that while there are still unknowns about monoclonal antibodies, such as real-life efficacy and long-term effects, they have the potential to effectively target several stages of the COVID-19 disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the world’s overburdened health systems).

The white paper finds that if their role is proven in time, there will be a high demand for monoclonal antibodies, and there is a clear opportunity for pharma companies to develop new antibodies.

“While slow in their uptake, the US distribution of monoclonal antibodies for COVID-19 has started and several companies are developing new antibodies,” said Alexander Fink, Managing Partner, Europe, Trinity Life Sciences. “Vaccines are still the focus; however, it is increasingly clear that vaccines alone are not enough. All in all, there is a place for antibodies in the fight against COVID-19.”

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Trinity Life Sciences


Release Summary
While there are still unknowns, monoclonal antibodies can help in the fight against COVID-19, according to a new white paper from Trinity.
Release Versions

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom